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Introduction
Breast cancer deaths are mostly caused by the systemic
disease, representing recurrences after definitive ther-
apy. Recent research efforts have focused on indenti-
fying markers in order to predict risk of  cancer out-
come [1]. 
While the patient qualification for further treatment
is obvious at extreme (I, III, and IV) stages of breast
cancer, the attitude in stage II cases is still conflicting.
It was estimated that only the low percentage of stage
II patients benefits from aggressive chemotherapy.
Consequently, it is of the major importance to define
the immunohistochemical features of this group which
could make  possible patients'stratification and indi-
vidualization of their treatment. 
Hepatocyte growth factor (HGF) belongs to the
plasminogen-prothrombin gene superfamily, which
includes macrophage-stimulating protein and plas-
minogen [2]. The growth promoting activity of HGF
requires proteolytic cleavage by extracellular serine
proteinases such as urokinase plasminogen activator
and tissue-type plasminogen activator [3]. HGF plays
a direct  role in stimulating blood vessel growth in
vitro and in vivo by signaling through the hepatocyte
growth factor receptor – (HGFR, c-met) which is
expressed on endothelial cells [4,5]. C-met is a mem-
ber of the receptor tyrosine kinases family and is
involved in the control of proliferation, survival and
morphogenesis of the normal and cancer cells. More-
over, the HGF-c-met pathway also contributes to
tumor progression by promoting angiogenesis through
the recruitment of new vessels [4]. C-met signaling is
involved in the regulation of tumor angiogenesis either
directly through the proangiogenic activity or indirect-
ly, through the regulated secretion of angiogenic fac-
tors such as VEGF-A [6]. 
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The vascular endothelial growth factors (VEGF)
family is a group of growth factors which regulate the
growth of endothelial cells [7]. VEGF is a cytokine
that selectively induces endothelial cell proliferation
and migration, increases the permeability of microves-
sels, and activates proteolytic enzymes involved in
tumor invasiveness [8]. Moreover, it stimulates the
growth of vascular endothelial cells derived from
arteries, veins and lymphatics. VEGF is also a survival
factor for endothelial cells, both in vitro and in vivo
[9]. Recent studies have demonstrated a prognostic
significance of VEGF-A expression in malignant
tumors arising from several organs [7,10-13]. Further-
more VEGF-A expressions in tumor tissues have been
reported to be an independent prognostic factor for
breast cancer patients regardless of the nodal status
[14,15]. 
HGFR signaling is implicated in a wide variety of
human malignancies, including the following ones:
melanoma, colon, gastric, bladder, breast, ovarian,
pancreatic, kidney, liver, lung, head and neck, thyroid
and prostate cancers [4,16,17,18]. Although there are a
number of studies demonstrating the overexpression of
c-met in breast cancer, there is no study comparing
VEGF-A and HGFR expressions in a very homoge-
nous group of patients with ductal breast carcinomas.
In this study we analyzed HGFR and VEGF expres-
sions, 5 and 10 years overall and disease free survival
(OS, DFS) and clinicopathological factors in highly
homogenous group of 98 patients with UICC stage II,
histological grade 2 and 3 ductal breast carcinomas
treated with primary modified radical mastectomy.
The aim of the work was to determine whether the
expressions of HGFR and VEGF-A in primary tumors
were correlated with lymph node metastasis, patients'
prognosis and could due to that fact be  helpful in
defining a subgroup of patients for more or less
aggressive treatment.
Materials and methods 
Patients and tumor samples. The present study includes archival
tumor samples from 98 patients of Lower Silesian Oncology Cen-
ter (Wroclaw, Poland) treated for stage II ductal breast cancer in
1993-1994. The study was approved by a regional Institutional
Review Board. The median age of the patients was 56, range from
29 to 86 years. All the patients underwent surgery (radical modi-
fied Patey-Madden mastectomy) with or without standard adjuvant
treatment. Information about the patients' clinical histories and
clinical and pathological variables was obtained from patients'
medical records and during follow-up visits. The size of primary
tumor was evaluated from the surgical specimen. Lymph node sta-
tus was determined by lymphadenectomy of axiliary lymph nodes
and by proving histological evidence of metastatic breast carcino-
ma. Overall survivals (OS, in weeks) and disease-free survivals
(DFS, in weeks) were established for all the patients. Follow-up
period amounted 5 years (261 weeks) and then 10 years (522
weeks) in all patients. Microscopic studies were performed on for-
malin-fixed, paraffin-embedded cancer tissues, obtained during
surgery and stained routinely with haematoxylin and eosin.
Histopathological type according to the World Health Organization
[19] (ductal breast cancer in all the cases), grade (only Bloom 2
and 3 were qualified to the experiment) and stage II according to
the TNM classification were determined during microscopic exam-
ination. Tumor grade was estimated according to Bloom-Richard-
son in the Elston and Ellis modification. The detailed characteris-
tics of patients are shown in Table 2. 
Immunohistochemistry. HGFR: Formalin-fixed paraffin embed-
ded, freshly cut 4 µm tissue sections were mounted on Superfrost
slides (Menzel Glaeser, Germany), dewaxed with xylene, and
gradually rehydrated. Sections were incubated with citrate buffer at
98°C to unmask the epitopes and treated with 1% hydrogen perox-
ide (H2O2) for 10 min to block endogenous peroxidase. The sec-
tions were then incubated with human hepatocyte growth factor
receptor mouse monoclonal antibody (from Novocastra Laborato-
ries Ltd). The sections were further incubated with biotin-labeled
secondary antibody and streptavidin-biotin-peroxidase, for 20 min
each. Tissues were  stained for 5 min with 0.05% 3,3'-
Diaminobenzidine tetrahydrochloride (DAB), counterstained with
haematoxylin, dehydrated and mounted (Figs. 1 and 2) [20].  
VEGF-A: Formalin-fixed paraffin embedded, freshly cut 4 µm
tissue sections were mounted on Superfrost slides (Menzel
Glaeser, Germany), dewaxed with xylene, and gradually rehy-
drated. Sections were incubated with citrate buffer at 98°C to
unmask the epitopes and treated with 1% hydrogen peroxide
(H2O2) for 10 min to block endogenous peroxidase. Then in the
next step sections were then incubated overnight in monoclonal
anti-VEGF165 antibody (from Novocastra Laboratories Ltd).
The sections were further incubated with biotin-labeled second-
ary antibody and streptavidin-biotin-peroxidase, for 20 min each.
Tissue was stained for 5 min with 0.05% 3,3'-Diaminobenzidine
tetrahydrochloride (DAB), counterstained with haematoxylin,
dehydrated and mounted (Figs. 3 and 4). Results of immunohis-
tochemical reactions were estimated independently by two
pathologists using the semi-quantitative score scale based on the
percentage of positive stained cells as follows: 0 = none, 1 level
– if up to 33%  cells in tumor were positive, 2 level – 33-66%
positive cells and 3 level if more than 66% cells were positive
[21]. In cases of controversy, a reevaluation was performed with
the use of a double-headed microscope.
Statistical analysis. The univariate significance of differences in
studied markers expressions was assessed by the chi-square test for
binary or categorical covariates, by Pearson test and by the Spear-
man rank correlation for ordered covariates. Cancer specific over-
all survival (OS) and disease free survival (DFS) were estimated
using the Kaplan-Meier method, and comparison between study
groups was performed with log-rank test. The survival time was
measured from date of diagnosis to date of death or last follow up.
In all tests, the significance level was set at 0.05 and all were two-
sided tests. Statistical analyses were performed using the Software
StatSoft Inc. STATISTICA for Windows ver. 7.0 A, Tulsa, OK,
USA.
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Table 1. HGFR and VEGF expression in breast cancer tissue
Results
HGFR expression in breast cancer tissue
In breast cancer cells, expressions of c-met protein
were observed in the cytoplasm. According to the cri-
teria accepted for c-met immunostaining level evalua-
tion, c-met protein positive were 63% (62 of 98 speci-
mens) of the breast cancer patient's tumor tissue sam-
ples (Table 1). 
VEGF-A expression in breast cancer tissue
In breast cancer cells, expression of VEGF-A was
observed in the cytoplasm (Table 1). According to the
criteria accepted for VEGF-A immunostaining level
evaluation, positive breast tissue samples were 69%
(68 of 98 specimens). 
Correlation between HGFR and VEGF-A
We observed significant correlation between those two
markers: in Pearson's test p=0.0176 and in Spearman's
rank correlation p=0.0205. 
Association between c-met and VEGF-A
expression and clinicopathological factors
No associations were observed between c-met and
VEGF-A expression and patients' age, tumor size,
tumor grade, ER status nor axillary lymph node metas-
tases (Table 2). 
Prognostic value of c-met and VEGF-A
in breast carcinoma patients
We examined whether c-met and VEGF-A expression
might be associated with poor prognosis in breast car-
cinoma patients. Five and 10 years OS and DFS were
analyzed in groups with different HGFR and VEGF-A
expression levels. With the time horizon of five and
ten years in both tests there was no significant differ-
ence found in overall and disease- free survival (Fig. 1
and 2).
Discussion
The importance of the HGF regulatory system in
development of cancer is still not fully understood. Up
to date  HGF is known to be a multifunctional cytokine
which induces cell proliferation, motility and angio-
genesis in a wide variety of neoplastic cells [22].  
In our study we have shown c-met expression in
63% of breast cancer patient's tumor tissue samples.
Masuya et al. [23] observed lower percentage of c-met
positive cells – 40.9% in non-small-cell lung cancer
and Endo et al. [24] noticed  42%  in squamous cell
cancer of tongue. Significantly higher percentage of c-
met immunopositivity was shown by Lo Muzio [25]   –
82.2% and Yucel [3] – 83% in head and neck squa-
mous cell cancer. In Ghoussoub et al. [26] studies only
20 of the 91 cases (22%) showed strong positive
expression of the c-met protein. The expression of
VEGF-A in our study was observed in 69% of breast
cancer patients. Yang et al. [27] observed expression
of VEGF-A in cytoplasmic staining in the majority of
breast carcinoma cells, whereas only weak expression
was found in nonmalignant breast tissue samples.
Other authors assessed only VEGF A levels in cytosol
of breast cancer tissues, without quantification, there-
fore we could not compare those results with ours
[8,28]. 
We observed significant correlations between
expression of HGFR and VEGF-A (p<0.05) but we
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Table 2. Distribution of breast ductal cancer patients according to HGFR and VEGF expression in tumor tissue
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Fig. 1. Invasive ductal carcinoma. Immunohistochemical reaction with anti-c-met antibody. Strong, diffuse reaction within neoplastic cells
(original magnification ×100). Fig. 2. DCIS and invasive ductal carcinoma. Immunohistochemical reaction with anti-c-met antibody.
Strong, diffuse reaction within intraductal component and dispersed neoplastic cells (original magnification ×100). Fig. 3. Invasive duc-
tal carcinoma, intraductal component. Immunohistochemical reaction with anti-VEGF antibody. Moderate, diffuse cytoplasmatic reaction
within neoplastic cells (original magnification ×100).  Fig. 4. Invasive ductal carcinoma. Immunohistochemical reaction with anti- VEGF
antibody. Strong, diffuse cytoplasmatic reaction within dispersed neoplastic glands and cells (original magnification ×200).
could not compare those results with data from other
authors because there is no available literature on this
subject. This correlation seems to be very interesting
because both markers play an important role in tumor
progression through angiostatin cooperation. Angio-
statin is a 38-kD peptid of plasminogen [29], which
interacts with vascular endothelial growth factor by a
selective inhibitory activity on sprouting angiogenesis.
This peptid counteracting with VEGF-A induced
migration of primary human microvascular endothelial
cells but without affecting intracellular signaling path-
ways known to regulate endothelial cell migration and
proliferation [30]. Thus, angiostatin may induce an
antiangiogenic cascade, and therefore control tumor
angiogenesis by supresing expression of VEGF [31]. 
Wajih and Sane [32] reported that recombinant
angiostatin kringles 1-3 inhibited HGF- induced phos-
phorylation of c-met and also inhibited downstream sig-
naling mediators in human endothelial cells in vitro.
Futhermore, HGF inhibited the binding of angiostatin to
human endothelial cells, and angiostatin inhibited HGF-
induced proliferation of these endothelial cells. The
ones, discovered in laboratories on tumors cell lines
relations may be an explanation of correlation between
expression of VEGF-A and c-met in our patients.  
In our study, 98 cases of invasive ductal breast can-
cer in II stage were analyzed for immunohistochemical
expression of c-met and VEGF-A in order to evaluate
the biological significance of this protein by testing
their associations with clinicopathological features.
No associations were observed between both markers
expression and patients age, tumor size, tumor grade,
ER status nor axillary lymph node metastases. The
same results for c-met observed Nakopoulou et al. [33]
in breast carcinoma and Osada et al. [34] in hepatocel-
lular carcinoma.  Other studies also did not find any
correlations between VEGF-A expression and clinico-
pathologic variables in breast cancer [8,27] and in
ovarian carcinoma [10].
On the contrary, Greenberg et al. [35] found that
positive c-met assays correlated with increased tumor
size, grade and lymph node metastases in breast cancer
tissues. Lo Muzio et al. [25] found correlations with c-
met expression and tumor stage in head and neck squa-
mous cell carcinoma. Manders et al. [28] showed that
in group of node-negative breast cancer patients a high
cytosolic levels of vascular endothelial growth factor-
A were associated with advanced age and tumor size.  
We did not find  any significant differences in over-
all- and disease- free survival in patients groups with
different HGFR and VEGF-A expression levels in the
time horizon of 5 and 10 years. Our data is  similar to
Nagy's et al. study concerning c-met [36] as well as
Toi et al. [37] and Byrnes et al. [1] studies concerning
VEGF-A in breast cancer patients. On the other way
opposite results concerning c-met [26,38-40] and
VEGF [41,42] expressions in patients with breast can-
cer were obtained in several studies. However in any
of above mentined experiments, ten years follow-up
was reported and similarly homogenous patients group
was assessed. Conflicting conclusions concerning
prognostic significance of c-met and VEGF-A expres-
sions suggest conducting study in larger homogenous
groups of patients with breast carcinoma.
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